ROS1 and non-small cell lung carcinoma: In an expansion cohort study of the PROFILE 1001 trial, 50 ROS1‐positive NSCLC patients demonstrated a high response rate (72%) and a median progression‐free survival (PFS) of 19.2 months when treated with crizotinib.8 Similarly, in an East Asian study, 127 ROS1‐positive NSCLC patients exhibited a response rate of 71.7% and a median PFS of 15.9 months.9